Rare & Orphan Lab · DeCure for X
DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for spondyloepiphyseal dysplasia congenita — screening already-approved drugs against its 5-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
No approved-drug candidate for spondyloepiphyseal dysplasia congenita is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
collagen type II alpha 1 chain (COL2A1) — COL2A1 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
RCSB Protein Data Bank · entry 5NIR · 1.74 Å · ligand 3,6,9,12,15,18-HEXAOXAICOSANE-1,20-DIOL (P33). Experimental structure, not a prediction.
Spondyloepiphyseal dysplasia (SED) is a group of rare skeletal disorders. A 1982 report describes a sporadic adult female with a distinctive variety of SED tarda, characterised by universal platyspondyly, short metacarpals and metatarsals, genu valgum, mild thoracic kyphoscoliosis, and severe generalised epiphyseal distortion with premature osteoarthrosis. A 1978 report describes three members of one family with SED Ribbing-Fairbank type, with a fourth member probably affected. A 1983 series of seven SED tarda cases reports a uniform clinical presentation of short stature with pains in the spine and large joints secondary to early osteoarthritic changes; hump-shaped lower thoracic and lumbar vertebral bodies are the diagnostic feature.
In 2025, the eighth reported case of spondyloepiphyseal dysplasia, Kondo-Fu type (SEDKF) was described: a 20-year-old male with severe disproportionate short stature, spondyloepiphyseal dysplasia, and the previously unreported feature of cutis laxa. Whole exome sequencing identified compound heterozygosity for a predicted splicing variant and a complete gene deletion in the MBTPS1 gene. Functional validation using RNA splicing assays confirmed aberrant splicing. The authors note that only seven SEDKF cases had been reported in the literature before this one.
No abstract reports any drug treatment, clinical trial, or intervention for any form of spondyloepiphyseal dysplasia. The 2025 case report broadens the clinical and molecular spectrum of MBTPS1-related disorders but does not test any therapy. What is missing is any clinical trial, any tested drug, any patient stratification strategy, and any funding directed toward treatment development for these conditions.
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
AbstractWe report a sporadic adult female with a distinctive variety of spondyloepiphyseal dysplasia tarda characterised by universal platyspondyly, short metacarpals, short metatarsals, genu valgum, mild thoracic kyphoscoliosis, and severe generalised epiphyseal distortion with premature osteoarthrosis.
https://doi.org/10.1136/jmg.19.3.234AbstractSpondyloepiphyseal Dysplasia Ribbing-Fairbank type in three members of a family are described. A fourth member of the family was also probably affected. The importance of the radiographic examination for the recognition of the disease is stressed and the radiographic differential diagnosis is reviewed.
https://doi.org/10.1111/j.1440-1673.1978.tb02071.xAbstractSUMMARY Seven cases of spondyloepiphyseal dysplasia tarda are reported. The disease has a very uniform clinical presentation ‐ shortening of stature with pains in spine and large joints secondary to early osteoarthritic changes ‐ with little variability. hump &aped lower thoracic and lumbar vertebral bodies are the diagnostic feature Of the disease.
https://doi.org/10.1111/j.1440-1673.1983.tb02452.xAbstractSpondyloepiphyseal dysplasia, Kondo-Fu (SEDKF) type is a rare skeletal dysplasia caused by biallelic variants in MBTPS1. To date, only seven SEDKF cases have been reported in the literature. Here, we report the eighth, a 20-year-old male presenting with severe disproportionate short stature, spondyloepiphyseal dysplasia, and the previously unreported feature of cutis laxa, which led to the clinical suspicion of geroderma osteodysplasica. Whole exome sequencing identified compound heterozygosity for a predicted splicing variant and a complete gene deletion in the patient. Functional validation using RNA splicing assays confirmed aberrant splicing, establishing the molecular diagnosis of SEDKF. This case broadens the clinical and molecular spectrum of MBTPS1-related disorders by presenting a novel combination of variants and phenotypic features.
https://doi.org/10.1111/cge.70084Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
